ArticleJournal of clinical lipidology
Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: The multi-ethnic study of atherosclerosis.
Article in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- The Evolving Role of Coronary Artery Imaging in Assessing Cardiovascular Risk from Lipoprotein(a).Current atherosclerosis reports · 2026Review
- Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study.Journal of the American College of Cardiology · 2026Article
- Association Between Lipoprotein(a) Testing, Lipid-Lowering Therapy Intensification, and Low-Density Lipoprotein Cholesterol Goal Attainment: Findings From the Veterans Affairs Health System.Journal of the American Heart Association · 2026Article
- Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention.Methodist DeBakey cardiovascular journal · 2026Review
- Genetic association between PCSK9 and coronary artery calcification mediated by inflammatory cytokines.Frontiers in cardiovascular medicine · 2026Article
- Lipoprotein(a) and plaque progression: insights from serial coronary computed tomography angiography and quantitative plaque assessment.Frontiers in cardiovascular medicine · 2026Article
- Age-Dependent Clinical Relevance of Lipoprotein(a): A Comprehensive Review from Childhood to Adulthood.Journal of clinical medicine · 2025Review
- Inconsistent association between lipoprotein(a) and coronary artery calcium.European journal of preventive cardiology · 2025Article
- Lp(a): Global Public Health Concern: Emerging Knowledge and Therapeutic Approaches.Current cardiology reports · 2025Review
- Association of lipoprotein(a) with progression of coronary artery calcification: retrospective longitudinal study.Korean journal of family medicine · 2025Article
- Lipoprotein(a): Assessing the Current Knowledge and Gaps in Screening and Treatment-A Narrative Review.Journal of cardiovascular development and disease · 2025Review
- The Association between Lipoprotein(a) and Coronary Artery Calcification in Elderly Patients with Diabetes: A Cross-Sectional Study.Reviews in cardiovascular medicine · 2025Article
- Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol.European journal of preventive cardiology · 2025Article
- Lipoprotein(a): Emerging insights and therapeutics.American journal of preventive cardiology · 2024Article
- Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment.Current atherosclerosis reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundCoronary artery calcium (CAC) scoring is often used for atherosclerotic cardiovascular disease (ASCVD) risk stratification in individuals with elevated lipoprotein(a) [Lp(a)].
objectiveTo evaluate associations between Lp(a) and baseline CAC (volume/density) and CAC progression compared to other lipid biomarkers.
methodsWe utilized data from the Multi-Ethnic Study of Atherosclerosis (MESA), a cohort study of individuals without clinical ASCVD, excluding statin users. We evaluated the associations between Lp(a), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), triglycerides, total cholesterol, apolipoprotein B, and non-HDL-C with baseline CAC and annual CAC progression using multivariable ordinal regression with adjustment for ASCVD risk factors. Analyses were also stratified by median age.
resultsIn 5,597 participants (2,726 at median 9.5-year follow-up), Lp(a) was not associated with baseline CAC volume or density and was modestly associated with volume progression (OR 1.11, 95% CI 1.03-1.21). However, other biomarkers were positively associated with baseline volume and volume progression (LDL-C: OR 1.26, 95% CI: 1.19-1.33 and OR 1.22, 95% CI: 1.15-1.30, respectively), except HDL-C which was inversely associated. LDL-C, total cholesterol and non-HDL-C were inversely associated with baseline density. In participants <62 years of age, Lp(a) was modestly associated with baseline CAC volume (OR 1.10, 95% CI: 1.00-1.20) and volume progression (OR 1.16 95% CI: 1.04-1.30).
conclusionsIn contrast to other lipid biomarkers, Lp(a) was not associated with baseline CAC volume or density and was only modestly associated with volume progression. Our findings suggest that Lp(a) is not as robustly associated with CAC as other lipid biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.